7.1 Ethics Approval and Consent to Participate
This study was approved by the Washington University Institutional Review Board and each participant provided signed informed consent.
7.2 Consent for Publication (individual person’s data)
7.3 Availability of data and materials
Data are available to qualified investigators upon request to the Knight ADRC (https://knightadrc.wustl.edu/Research/ResourceRequest.htm) and ADNI (http://adni.loni.usc.edu/data-samples/access-data/).
7.4 Competing Interests
AMF is a member of the scientific advisory boards for Roche Diagnostics, Genentech and AbbVie and also consults for Araclon/Grifols, DiademRes, DiamiR and Otsuka Pharmaceuticals. All remaining authors report no conflict of interest.
This project was funded by National Institute on Aging (NIA) grants R03AG050921 (SES, PI) and K23AG053426 (SES, PI). Data from the Knight ADRC cohort was funded by NIA grants P50 AG05681 (JCM, PI), P01 AG03991 (JCM, PI), and P01 AG026276 (JCM, PI).
In addition, data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
7.6 Author contributions
O.H.B analyzed the data and wrote the manuscript. J.M.L aided in preparing the manuscript and provided critical manuscript review. R.L.H. ran samples and performed quality-control for assays. E.H. aided in the development, validation, and quality-control of the assays. C.L.S completed preliminary data analyses and ran samples. A.M.F provided critical manuscript review. C.C. provided critical manuscript review. D.M.H provided critical manuscript review. J.C.M. provided participant characterization and provided critical manuscript review. B.M.A. helped prepare the manuscript and provided critical manuscript review. S.E.S performed the initial data analysis, helped prepare the manuscript and provided critical manuscript review. All authors read and approved the final manuscript.
We thank all participants at the Knight Alzheimer Disease Research Center for their role in the sample provision and data collection. This work was also supported by the generous support of Barnes-Jewish Hospital, the Knight Alzheimer Disease Research Center, the Hope Center for Neurological Disorders, the Paula and Rodger O. Riney Fund, the Daniel J. Brennan MD Fund, and the Fred Simmons and Olga Mohan Fund.